Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 9,925 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 9,925 shares of the company’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $65.47, for a total transaction of $649,789.75. Following the completion of the sale, the insider now directly owns 86,596 shares in the company, valued at $5,669,440.12. This trade represents a 10.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, May 16th, Martina M.D. Flammer sold 1,799 shares of Insmed stock. The stock was sold at an average price of $67.53, for a total value of $121,486.47.
• On Wednesday, May 14th, Martina M.D. Flammer sold 1,744 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $114,423.84.
• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total value of $570,146.48.

Insmed Stock Down 0.4%

Insmed stock traded down $0.24 during midday trading on Monday, hitting $67.88. The stock had a trading volume of 1,334,593 shares, compared to its average volume of 2,325,724. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business has a fifty day moving average price of $71.57 and a 200 day moving average price of $73.16. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The stock has a market cap of $12.36 billion, a P/E ratio of -12.14 and a beta of 0.84.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same quarter last year, the business earned ($1.06) earnings per share. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. Research analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Institutional Trading of Insmed

Several institutional investors have recently modified their holdings of the company. Cullen Frost Bankers Inc. increased its holdings in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 221 shares in the last quarter. Elequin Capital LP acquired a new position in shares of Insmed in the fourth quarter worth $28,000. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares in the last quarter. NBC Securities Inc. acquired a new position in shares of Insmed during the 1st quarter worth $49,000. Finally, V Square Quantitative Management LLC raised its holdings in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Monday, May 12th. Guggenheim reiterated a “buy” rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Jefferies Financial Group began coverage on shares of Insmed in a research report on Tuesday, May 13th. They set a “buy” rating and a $105.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. Finally, Bank of America boosted their price objective on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $94.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.